CERo Therapeutics Holdings (CERo Therapeutics Holdings) Accounts Payable & Accrued Expense : $0.47 Mil (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Accounts Payable & Accrued Expense?

CERo Therapeutics Holdings's quarterly accounts payable & accrued expense increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.49 Mil) but then declined from Dec. 2021 ($0.49 Mil) to Dec. 2022 ($0.47 Mil).

CERo Therapeutics Holdings's annual accounts payable & accrued expense increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.49 Mil) but then declined from Dec. 2021 ($0.49 Mil) to Dec. 2022 ($0.47 Mil).

CERo Therapeutics Holdings Accounts Payable & Accrued Expense Historical Data

The historical data trend for CERo Therapeutics Holdings's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Accounts Payable & Accrued Expense Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Accounts Payable & Accrued Expense

0.49

0.47

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Accounts Payable & Accrued Expense	0.49	0.47

CERo Therapeutics Holdings Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024